2 weeks Ago By ABMN Staff
Dimensional Fund Advisors LP lifted its position in Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ) by 6.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 708,624 shares of the biotechnology company’s stock after acquiring an additional 44,543 shares during the quarter.
Dimensional Fund Advisors LP owned 3.94% of Ligand Pharmaceuticals worth $59,707,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently made changes to their positions in the company.
Envestnet Asset Management Inc. raised its holdings in shares of Ligand Pharmaceuticals by 47.7% in the second quarter.
Envestnet Asset Management Inc. now owns 79,612 shares of the biotechnology company’s stock valued at $6,708,000 after acquiring an additional 25,717 shares in the last quarter. William Blair Investment Management LLC raised its holdings in shares of Ligand Pharmaceuticals by 7.
2% in the second quarter. William Blair Investment Management LLC now owns 202,842 shares of the biotechnology company’s stock valued at $17,091,000 after acquiring an additional 13,595 shares in the last quarter. American Century Companies Inc.
raised its holdings in shares of Ligand Pharmaceuticals by 16.4% in the second quarter. American Century Companies Inc.
now owns 29,167 shares of the biotechnology company’s stock valued at $2,458,000 after acquiring an additional 4,104 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of Ligand Pharmaceuticals by 4.5% in the second quarter.
Rice Hall James & Associates LLC now owns 292,475 shares of the biotechnology company’s stock valued at $24,644,000 after acquiring an additional 12,691 shares in the last quarter. Finally, Headlands Technologies LLC grew its stake in Ligand Pharmaceuticals by 21.7% in the second quarter.
Headlands Technologies LLC now owns 758 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 135 shares during the last quarter. 91.28% of the stock is currently owned by institutional investors.
Ligand Pharmaceuticals Stock Performance Shares of LGND stock opened at $97.37 on Friday. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $49.
24 and a fifty-two week high of $112.13. The firm has a market capitalization of $1.
75 billion, a price-to-earnings ratio of 18.83 and a beta of 1.01.
The stock’s 50-day simple moving average is $102.88 and its 200-day simple moving average is $88.42.
Insider Transactions at Ligand Pharmaceuticals In other news, insider Andrew Reardon sold 1,500 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $106.39, for a total transaction of $159,585.
00. Following the sale, the insider now owns 22,534 shares in the company, valued at $2,397,392.26.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . In related news, COO Matthew E. Korenberg sold 18,245 shares of Ligand Pharmaceuticals stock in a transaction dated Friday, August 9th.
The stock was sold at an average price of $98.50, for a total transaction of $1,797,132.50.
Following the completion of the sale, the chief operating officer now owns 68,368 shares of the company’s stock, valued at $6,734,248. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website . Also, insider Andrew Reardon sold 1,500 shares of Ligand Pharmaceuticals stock in a transaction dated Wednesday, August 28th.
The stock was sold at an average price of $106.39, for a total value of $159,585.00.
Following the sale, the insider now directly owns 22,534 shares of the company’s stock, valued at approximately $2,397,392.26. The disclosure for this sale can be found here .
Over the last 90 days, insiders have sold 51,613 shares of company stock worth $5,255,692. Insiders own 5.90% of the company’s stock.
Analyst Ratings Changes Several equities analysts have issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $130.00 target price on shares of Ligand Pharmaceuticals in a research note on Wednesday, August 7th.
HC Wainwright reiterated a “buy” rating and issued a $144.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday, August 8th. Craig Hallum lifted their target price on Ligand Pharmaceuticals from $135.
00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Finally, Benchmark lifted their target price on Ligand Pharmaceuticals from $95.
00 to $110.00 and gave the company a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock.
According to MarketBeat.com, Ligand Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $131.00.
View Our Latest Analysis on LGND Ligand Pharmaceuticals Company Profile ( Free Report ) Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. Further Reading Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ). Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
